Objectives: Differences in outcomes for women and men after percutaneous coronary intervention (PCI) in older patients remain controversial. Herein, we compared 2-year outcomes by sex in Chinese older patients undergoing PCI.
of mortality, and have higher rates of comorbidities, unfavorable conditions, and complex coronary lesions. 3 Nevertheless, older patients are often underrepresented or even excluded in randomized clinical trials evaluating primary PCI.
The relationship between sex and outcomes after CAD in older patients remains controversial because of conflicting data. It is well established that women are significantly older at presentation, have a higher frequency of coronary traditional risk factors such as diabetes mellitus and hypertension, and experience more comorbidities, resulting in increased major adverse cardiovascular and cerebrovascular events (MACCE) compared with men. [4] [5] [6] However, few studies have reported associations of non-modifiable risk factors of age and sex with long-term bleeding post-PCI in women with CAD. Recently, younger women (≤55 years old) were reported to be at particularly high risk of bleeding post-PCI because of baseline differences such as anti-platelet/anticoagulation therapy, pre-procedural anemia, renal impairment, femoral access, and the proportion of ST-elevation myocardial infarction (STEMI) patients. 7, 8 By contrast, other studies have shown that radial access does not reduce the risk of bleeding or vascular complications post-PCI compared with femoral access in women. 9, 10 Further, the long-term clinical outcomes of women and men with CAD ≥60 years of age who received PCI in China are unknown. Thus, the aim of this study was to compare the baseline characteristics, management, and long-term ischemic and bleeding outcomes in women versus men with CAD in a large Chinese observational study.
2 | METHODS
| Study population
Data from all consecutive patients from a single center (Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China) undergoing PCI were collected. Between January 2013 and December 2013, a total of 4926 consecutive older patients receiving PCI were enrolled. Patients were stratified by sex. Patients undergoing PCI in the setting of stable angina pectoris, non-STEMI/unstable angina pectoris, or STEMI were evaluated. We selected a cutoff of 60 years of age to differentiate between younger and older patients, with older patients defined as those ≥60 years in China. Baseline characteristics, PCI procedures, management, and long-term outcomes were collected prospectively from medical records and reports within the cardiology department and hospital laboratory databases, and then analyzed. The
Institutional Review Board approved the study protocol, and the patients provided written informed consent before the intervention.
| Procedures and medications
The PCI strategy and stent type were left to the discretion of the treating physician. If patients were not taking long-term aspirin and P2Y12 inhibitors, selected PCI patients received oral aspirin (300 mg) and clopidogrel (300 mg loading-dose) or ticagrelor (180 mg loading dose) at least 24 h before the procedure. Acute coronary syndrome (ACS) patients (STEMI and non-ST segment elevation ACS) scheduled for PCI received the same dose of aspirin and clopidogrel or ticagrelor as soon as possible. During the procedure, unfractionated heparin (100 U/kg) was administered to all patients, and glycoprotein IIb/IIIa inhibitors were used based on the judgment of the operator. After the procedure, aspirin was prescribed (100 mg daily) indefinitely, and clopidogrel (75 mg daily) or ticagrelor (90 mg twice daily) was advised for at least 1 year after PCI.
| Endpoints and definitions
Death that could not be attributed to a non-cardiac etiology was considered cardiac death. MI was defined by the third universal definition. 11 Revascularization was defined as repeated revasculariza- 3 | RESULTS
| Baseline characteristics
Patients stratified by sex and baseline characteristics are summarized in Table 1 . The study cohort included 4926 patients with CAD who underwent PCI. Of these, 1655 (33.6%) were women. The mean age was 67.0 ± 5.7 years, and women were 1.1 years older than men (68.1 vs 67.0 years, P < 0.001). Women had a higher frequency of several baseline risks, including the prevalence of diabetes mellitus (34.9% vs 30.0%, P = 0.003), hypertension (75.3% vs 66.3%, P < 0.001). Men were more likely to be smokers, and have a history of PCI, CABG, and MI. Women and men had a similar body mass index, prevalence of chronic obstructive pulmonary disease and cerebrovascular disease, and history of family CAD. Compared with men, women more had lower estimated glomerular filtration rate (eGFR) (81.6 ± 15.6 vs 84.0 ± 13.4 mL/min/1.73 m 2 , P < 0.001) and hemoglobin (128.7 ± 12.8 vs 143.9 ± 14.4 g/L, P < 0.001).
The procedural differences and medical treatments between sexes are shown in Table 2 . With respect to angiographic and procedural characteristics, women presented with lower use of radial access than men (85.4% vs 88.1%, P = 0.006). Women also had a lower prevalence of left main coronary artery disease than men (1.9% vs 18.2%, P = 0.006), but similar rates of multivessel disease. Women and men had a similar number of stent implants, types of stents, and application of intra-aortic ballon pump (IABP). The PCI success rate was identical between sexes. We also compared medical management at discharge/in-hospital between sexes. Compared with men, women received similar medication with β-blockers and proton pump inhibitors, but higher doses of calcium channel blockers. With respect to anti-platelet treatment as a peri-intervention application, and low molecular weight heparin were also similar between the two groups. However, men had a higher prevalence of thrombolysis for acute myocardial infarction (AMI) patients compared with women (2.1% vs 0.9%, P = 0.003). At 2-year follow up, the anti-platelet treatment rate was similar between the two groups.
| In-hospital and 2-year clinical outcomes
The in-hospital and 2-year clinical outcomes in men and women are shown in Table 3 . Compared with men, women had significantly higher rates of in-hospital all-cause mortality (0.2% vs 0.8%, P = 0.001), cardiac death (0.1% vs 0.5%, P = 0.006), MACCEs (1.5% vs 2.4%, P = 0.017), and bleeding (0.1% vs 0.4%, P = 0.017). At 2-year follow up, there were no differences between men and women in all-cause mortality (1.9% vs 1.8%, P = 0.839), MI (2.1% vs 2.4%, P = 0.626), unplanned revascularization (8.4% vs 7.1%, P = 0.109), stent thrombosis (1.1% vs 0.9%, P = 0.466), stroke (1.7% vs 2.2%, P = 0.232), or MACCEs (13.1% vs 11.8%, P = 0.216). However, women had significantly higher rates of BARC bleeding than men (9.2% vs 6.2%, P < 0.001). The types of BARC bleeding rate are shown in Table 4 .
Kaplan-Meier analysis according to the BARC bleeding-free survival also revealed a higher occurrence of bleeding in women than men (Figure 1) . Thus, we performed univariate and multivariate 
| DISCUSSION
The present study provides new data on the sex-related differences in older patients after PCI in a large Chinese cardiovascular center. We found that 33.6% of all PCIs were performed in women. Further, older women undergoing PCI were at increased risk of in-hospital and 2-year bleeding compared with men (there were no sex differences in mortality and MACCE at 2-year follow up), and after adjusting for differences in baseline and treatment characteristics, female sex remained an independent predictor of 2-year BARC bleeding.
In the present cohort, women with PCI were older than men, and more frequently presented with hypertension, diabetes mellitus, and hyperlipidemia. Older women also had lower hemoglobin and eGFR levels, as previously reported. [4] [5] [6] Although these findings are in accordance with previous studies, univariate and multi-variable analyses indicated that these variables were not independent risk factors for 2-year bleeding. Pre-procedural anemia and renal dysfunction were previously shown to be independently associated with increased bleeding post-PCI. 14, 15 In the present study, we did not transform the eGFR or hemoglobin into categorical variables such as chronic renal disease or anemia, which may have contributed to these contrasting findings. We also found no differences in medical treatment between sexes, including use of medication with dual anti-platelets, anticoagulants, and GPIs. Thus, the increased 2-year bleeding risk in women could not be explained by treatment differences, which also contrasts with recent studies showing that antiplatelet and anticoagulant treatment increased the bleeding risk in women. 
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FIGURE 1 Kaplan-Maier curves for Bleeding Between Female and Male Group
Previous studies of sex-associated differences in MACE and mortality are conflicting. For example, several studies indicated that although rates of MACE and mortality post PCI for stable angina pectoris and ACS were higher in women than in men, the results were no longer significant after adjusting for baseline characteristics. 17, 18 By contrast, other studies found that female sex was a significant predictor of MACE and/or mortality after PCI, even after multivariable adjustment. 17, 18 However, accumulating evidence suggests that there are no differences in long-term mortality after PCI between older women and men. 19 In the present study, the rates of 2-year MACCE, all causes of mortality, and other secondary endpoints including MI, TVR, ST, and stroke were similar between sexes.
Our findings are in accordance with other studies suggesting that the clinical outcome for older women is similar to that for older men following CAD. For example, Liu et al, reported that at an average of driven by a higher rate of cardiac rehospitalization (mainly congestive heart failure). 21 A possible explanation for these varying findings is the inclusion criteria of the study populations, such as the cut-off age in older patients and the inclusion range of coronary heart disease. Indeed, some studies included patients with a broader range of CAD, while some examined those with ACS or only STEMI. Further, the differences in long-term outcome between women and men were not always examined. The selection criteria and clinical end points are important for analysis of sex-based differences. In the present study, we included a relatively broader range of men and women with CAD ≥60 years of age who received PCI, which may have affected our findings.
Prior studies of sex-based differences in short-and long-term bleeding rates have shown conflicting results, with reports of both no differences and significant associations between female sex and increased 30-day major bleeding, which remained significant after multivariable adjustment. 6, 22 In the present study, older women had a higher unadjusted rate of 2-year bleeding compared with men, even after adjustment for baseline differences. This finding is similar to the HORIZONS-AMI trial substudy, in which women had a less favorable cardiovascular risk profile compared with men, and had significantly higher rates of 3-year MACE and major bleeding. 23 In that study, after adjusting for differences in baseline and treatment characteristics, female sex remained an independent predictor of poor outcomes in terms of long-term major bleeding, but not of overall MACE or death.
Differences in the definition of major bleeding used in these studies may also contribute to the varying results. 16, 23 We used the BARC bleeding definition criteria, which provides a balanced combination of laboratory and clinical metrics for bleeding recognition. 16 We also included the BARC bleeding types 1, 2, 3, and 5 in our analyses, and found that out of a total of 355 bleeding cases, >50% were type 1 (194).
By contrast, other studies only included the BARC type 2-5 bleeding events. 8 In addition, older patients were reported to be at higher risk for minor and major bleeding after administration of GPIs, although we found similar rates of GPI and P2Y12 receptor antagonist treatment in older patients. 7 We also found that women had higher rates of femoral access procedures, which is associated with increased risk of bleeding events compared with the radial route. 24 Finally, pre-procedural anemia may be a further cause of variability, as it was independently associated with increased bleeding, as previously reported. 25 
| Study limitations
A major limitation of this study was the use of observational analysis of registry data that were not adjudicated. Thus, bleeding and ischemic events were subject to underreporting. All the patients were also from a single center, and the mean age of the included patients was 67.0 ± 5.7 years, which was relatively young and may have introduced selection bias. Further, the patients received a relatively high dose of unfractionated heparin (100 U/kg), while activated clotting time was not measured. In addition, we did not collect information on the proportion of patients taking oral anticoagulants and having triple therapy. Finally, although we assessed the type of bleeding, the source or site of bleeding was unknown.
| CONCLUSIONS
We found that older women with CAD had a poorer baseline risk profile, and were independently associated with an increased risk of 2-year bleeding, compared with older men. However, there were no differences in risk of mortality, MACCE, or individual ischemic end points between women and men. With the increasing prevalence of traditional risk factors in older patients, greater attention to lowering baseline risks using focused secondary prevention strategies are required, particularly in older women. Further studies are also required to explore sex-based differences for older patients with PCI.
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